A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua.

Piroxicam beta-cyclodextrin has recently been observed to be equal to, or even possibly to be superior to, indomethacin (mainly with regard to side effects) in a single case of hemicrania continue. Piroxicam beta-cyclodextrin, 20 to 40 mg per day, was, accordingly, tried in six patients with chronic paroxysmal hemicrania and six patients with hemicrania continua with a previously proven response to indomethacin. The study was conducted over a period of 3 weeks and in an open fashion. A placebo effect is considered to be negligible in these disorders. In such a comparison, piroxicam beta-cyclodextrin seemed inferior to indomethacin, in particular in chronic paroxysmal hemicrania.
AuthorsO Sjaastad, F Antonaci
JournalHeadache (Headache) Vol. 35 Issue 9 Pg. 549-50 (Oct 1995) ISSN: 0017-8748 [Print] UNITED STATES
PMID8530280 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Piroxicam
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Middle Aged
  • Migraine Disorders (drug therapy)
  • Piroxicam (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: